{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T23:48:24Z","timestamp":1794700104496,"version":"4.9.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who harbor del(17p) and\/or tumor protein p53 (TP53) mutations represent a high-risk population with a historically poor prognosis. To assess zanubrutinib efficacy and safety outcomes in patients with CLL\/SLL with del(17p) and\/or TP53 mutations (N = 301; n = 132, treatment-naive [TN]; n = 169, relapsed\/refractory [R\/R]), data from SEQUOIA (phase 3; TN; zanubrutinib; NCT03336333), ALPINE (phase 3; R\/R; zanubrutinib vs ibrutinib; NCT03734016), and AU-003 (NCT02343120) (phase 1\/2; zanubrutinib) were evaluated. In SEQUOIA (n = 127; median follow-up, 64.8 months), median progression-free survival (PFS) and overall survival (OS) were not reached; estimated 60-month PFS and OS were 70.7% and 82.3%, respectively. In ALPINE (n = 75, each treatment arm; median follow-up, 39.0 months), 36-month PFS rates were 59.2% among patients treated with zanubrutinib and 38.5% among those treated with ibrutinib, and OS rates were 73.6% and 72.5%, respectively. In AU-003 (n = 24; median follow-up, 69.6 months), 10 of 24 patients experienced progressive disease. Rate of response with zanubrutinib in SEQUOIA was 96.9% (95% confidence interval [CI], 95.2-98.8), and in ALPINE was 89.3% (95% CI, 80.1-95.3) with zanubrutinib vs 76.0% (95% CI, 64.7-85.1) with ibrutinib. Responses deepened over time in both TN and R\/R populations. The most frequent nonhematologic treatment-emergent adverse events occurring in &amp;gt;20% of patients treated with zanubrutinib with del(17p) and\/or TP53 mutations in SEQUOIA and ALPINE were COVID-19, upper respiratory tract infection, arthralgia, diarrhea, and contusion. In conclusion, zanubrutinib demonstrated strong efficacy in high-risk del(17p) and\/or TP53 CLL\/SLL, with a tolerable safety profile, further supporting use of zanubrutinib in both frontline and R\/R settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015986","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T20:06:54Z","timestamp":1755634014000},"page":"694-706","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Zanubrutinib for the treatment of patients with del(17p) and\/or\n                    <i>TP53<\/i>\n                    CLL\/SLL: analysis across clinical studies"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"first","affiliation":[{"name":"1Department of Haematology, Alfred Hospital and Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-0215","authenticated-orcid":false,"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"},{"name":"3Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-5334","authenticated-orcid":false,"given":"Martin","family":"\u0160imkovi\u010d","sequence":"additional","affiliation":[{"name":"44th Department of Internal Medicine-Haematology, University Hospital and Charles University in Prague, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology, Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"},{"name":"6Division of Experimental Oncology, Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":false,"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"7Center for Blood Cancers, Tennessee Oncology\/OneOncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"8Hematology Department, Centre Hospitalier du Mans, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"9Department of Haematology, Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Cull","sequence":"additional","affiliation":[{"name":"10Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"11Department of Haematology, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Karolinska University Hospital Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"13Department of Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wang","sequence":"additional","affiliation":[{"name":"14BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9195-6520","authenticated-orcid":false,"given":"Andy","family":"Szeto","sequence":"additional","affiliation":[{"name":"14BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Allewelt","sequence":"additional","affiliation":[{"name":"14BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Salmi","sequence":"additional","affiliation":[{"name":"15BeOne Medicines Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Li","sequence":"additional","affiliation":[{"name":"14BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Xu","sequence":"additional","affiliation":[{"name":"14BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wu","sequence":"additional","affiliation":[{"name":"14BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remus","family":"Vezan","sequence":"additional","affiliation":[{"name":"14BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"16Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"17Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"18Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"5","key":"2026021015530681300_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N Engl J Med"},{"issue":"10129","key":"2026021015530681300_bib2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"2026021015530681300_bib3","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.4161\/cc.7.24.7245","article-title":"Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway","volume":"7","author":"Zenz","year":"2008","journal-title":"Cell Cycle"},{"issue":"26","key":"2026021015530681300_bib4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"21","key":"2026021015530681300_bib5","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"31","key":"2026021015530681300_bib6","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026021015530681300_bib7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10232","key":"2026021015530681300_bib8","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"2026021015530681300_bib9","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/bloodadvances.2023011741","article-title":"Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia","volume":"8","author":"Stilgenbauer","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026021015530681300_bib10","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"2026021015530681300_bib11","unstructured":"BRUKINSA (zanabrutinib) EMA prescribing information. European Medical Agency. 2021. Accessed 6 February 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/brukinsa."},{"key":"2026021015530681300_bib12","unstructured":"BRUKINSA (zanabrutinib) US prescribing information. BeiGene USA Inc. 2019. Accessed 26 August 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213217s005lbl.pdf."},{"issue":"2","key":"2026021015530681300_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cts.12948","article-title":"Population pharmacokinetic analysis of the BTK inhibitor zanubrutinib in healthy volunteers and patients with B-cell malignancies","volume":"14","author":"Ou","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"17","key":"2026021015530681300_bib14","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"issue":"8","key":"2026021015530681300_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026021015530681300_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"2026021015530681300_bib17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/bjh.17994","article-title":"Zanubrutinib for treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I\/II AU-003 study","volume":"196","author":"Cull","year":"2022","journal-title":"Br J Haematol"},{"issue":"11","key":"2026021015530681300_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"2026021015530681300_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-4419-1688-4_3","volume-title":"The Principles of Clinical Cytogenetics","author":"Slovak","year":"2013","edition":"3rd ed"},{"issue":"26","key":"2026021015530681300_bib20","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026021015530681300_bib21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026021015530681300_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2026021015530681300_bib23","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/bloodadvances.2023011307","article-title":"Acalabrutinib-based regimens in frontline or relapsed\/refractory higher-risk CLL: pooled analysis of 5 clinical trials","volume":"8","author":"Davids","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026021015530681300_bib24","doi-asserted-by":"crossref","first-page":"e89904","DOI":"10.1172\/jci.insight.89904","article-title":"Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib","volume":"2","author":"Burger","year":"2017","journal-title":"JCI Insight"},{"issue":"9","key":"2026021015530681300_bib25","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/psp4.13010","article-title":"Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models","volume":"12","author":"Ibrahim","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"18","key":"2026021015530681300_bib26","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2026021015530681300_bib27","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2026021015530681300_bib28","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2026021015530681300_bib29","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2026021015530681300_bib30","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","article-title":"Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma","volume":"4","author":"Tam","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2026021015530681300_bib31","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2011-11-395269","article-title":"Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with \"normal\" FISH: correlations with clinicobiologic parameters","volume":"119","author":"Rigolin","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2026021015530681300_bib32","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.3390\/cancers16152732","article-title":"Chronic lymphocytic leukemia: prognostic factors in the era of novel drugs","volume":"16","author":"Urso","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026021015530681300_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2026021015530681300_bib34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.pathol.2024.05.002","article-title":"The hidden Australian skin cancer epidemic, high-risk cutaneous squamous cell carcinoma: a narrative review","volume":"56","author":"Dettrick","year":"2024","journal-title":"Pathology"},{"issue":"12","key":"2026021015530681300_bib35","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/imj.13261","article-title":"Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients","volume":"46","author":"Hock","year":"2016","journal-title":"Intern Med J"},{"issue":"7","key":"2026021015530681300_bib36","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study","volume":"105","author":"Royle","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"2026021015530681300_bib37","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/694\/2501479\/blooda_adv-2025-015986-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/694\/2501479\/blooda_adv-2025-015986-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:53:18Z","timestamp":1770756798000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/3\/694\/546754\/Zanubrutinib-for-the-treatment-of-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015986","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,10]]},"published":{"date-parts":[[2026,1,29]]}}}